Melatonin in nighttime blood pressure in African-Americans with essential hypertension: results from two randomized placebo-controlled clinical trials (map-trials)
| Autor: | Frederic F. Rahbari-Oskoui, George Cotsonis, Arlene B. Chapman, Adam A. Bruckman, Jerome L. Abramson, Donald L. Bliwise, Sarah J Johnson |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
business.industry Hazard ratio Placebo Essential hypertension medicine.disease Clinical trial Melatonin Blood pressure Fatal-Plus Anesthesia Internal medicine Attributable risk Internal Medicine medicine Cardiology Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Journal of the American Society of Hypertension. 8:e2 |
| ISSN: | 1933-1711 |
| DOI: | 10.1016/j.jash.2014.07.010 |
| Popis: | tively. While accounting for family clusters, the hazard ratios associated with TT homozygosity were 4.11 (1.53-11.1; P1⁄40.0052) for cardiovascular mortality (4 deaths), 2.75 (1.32-5.73; P1⁄40.0067) for cardiovascular events (7 endpoints), and 3.10 (1.18-8.17; P1⁄40.022) for coronary events (4 endpoints). With adjustment for cardiovascular risk factors, these hazard ratios were 6.01 (2.26-16.0; P1⁄40.0003), 2.64 (1.27-5.46; P1⁄40.0091), and 2.89 (1.28-6.50; P1⁄40.010), respectively. Analyses not adjusted for blood pressure and antihypertensive treatment produced consistent results. For all of the fatal plus nonfatal cardiovascular events, the positive predictive value, attributable risk, and population-attributable risk associated with TT homozygosity were 21.9%, 61.5%, and 2.0%, respectively. In conclusion, TT homozygosity at position -665 in the eNOS promoter predicts adverse outcomes, independent of blood pressure and other cardiovascular risk factors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|